The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon

• Published in: British journal of clinical pharmacology Vol. 25; no. 6; pp. 751 - 754
• Main Authors: Francis, JL, Roath, OS, Challenor, VF, Waller, DG
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.1988; Blackwell Science
• Subjects: Adult; Aged; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Calcium Channel Blockers - pharmacology; Female; Humans; Male; Medical sciences; Middle Aged; Nifedipine - analogs & derivatives; Nifedipine - pharmacology; Nisoldipine; Pharmacology. Drug treatments; Platelet Aggregation - drug effects; Raynaud Disease - blood; Aggregation; Multiple dose; Human; Raynaud syndrome; Chemotherapy; Platelet; Treatment; Calcium antagonist; Double blind study; Cardiovascular disease; Controlled therapeutic trial
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/j.1365-2125.1988.tb05262.x

1. Whole blood platelet aggregation was measured by electrical impedance in 28 controls and 28 patients with primary Raynaud's phenomenon. 2. The patients were entered into a double‐blind, placebo‐ controlled cross‐over trial of the calcium antagonist nisoldipine, in which they received, in random order, three, 4 week treatments with placebo and nisoldipine (5 and 10 mg day‐1). 3. Platelet aggregation responses to two concentrations (5.0 and 0.5 micrograms ml‐1) of collagen were determined before treatment and at the end of each treatment phase. 4. There were no differences in aggregation response to either collagen concentration between controls and patients with primary Raynaud's phenomenon, or between placebo and active treatment phases. 5. These data do not support the suggestion that nisoldipine has a significant anti‐platelet effect.